Disc Medicine Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants
June 13, 2023 22:39 ET
|
Disc Medicine Inc
WATERTOWN, Mass., June 13, 2023 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization...
Disc Medicine Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
June 12, 2023 16:00 ET
|
Disc Medicine Inc
WATERTOWN, Mass., June 12, 2023 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization...
Disc Presents Positive Initial Data from Phase 2 BEACON Trial of Bitopertin in Patients with Erythropoietic Protoporphyria (EPP) at European Hematology Association (EHA) 2023 Congress
June 09, 2023 07:00 ET
|
Disc Medicine Inc
Consistent and dose-dependent reductions of protoporphyrin IX (PPIX), the disease-causing metabolite in EPP, were observed in patients treated with bitopertin Patients reported significant...
Disc Medicine to Participate in the Jefferies Healthcare Conference
May 31, 2023 16:00 ET
|
Disc Medicine Inc
WATERTOWN, Mass., May 31, 2023 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel...
Disc Medicine Reports First Quarter 2023 Financial Results and Provides Business Update
May 15, 2023 07:00 ET
|
Disc Medicine Inc
Two ongoing Phase 2 studies of bitopertin in EPP; initial safety and efficacy data from open-label BEACON trial to be presented at the European Hematology Association (EHA) Congress in June 2023;...
Disc Medicine Announces Presentation of Initial Data from Phase 2 BEACON Trial in Patients with Erythropoietic Protoporphyria (EPP) at European Hematology Association (EHA) 2023 Congress
May 11, 2023 10:15 ET
|
Disc Medicine Inc
WATERTOWN, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel...
Disc Medicine to Participate in H.C. Wainwright BioConnect Investor Conference
April 21, 2023 08:30 ET
|
Disc Medicine Inc
WATERTOWN, Mass., April 21, 2023 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of...
Disc Medicine to Host Disease Webinar with KOLs on Erythropoietic Protoporphyria (EPP)
April 13, 2023 11:00 ET
|
Disc Medicine Inc
WATERTOWN, Mass., April 13, 2023 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of...
Disc Medicine Reports Full Year 2022 Financial Results and Provides Business Update
March 31, 2023 07:00 ET
|
Disc Medicine Inc
Completed reverse merger with Gemini Therapeutics, debuting on Nasdaq as “IRON” and ending 2022 with approximately $194.6 million in cash and cash equivalentsInitiated two Phase 2 trials, AURORA and...
Disc Medicine Announces Collaboration with National Institutes of Health for Phase 2 Clinical Study of Bitopertin in Patients with Diamond-Blackfan Anemia (DBA)
March 21, 2023 07:00 ET
|
Disc Medicine Inc
WATERTOWN, Mass., March 21, 2023 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of...